MedTrace Logo

Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer

NCT00130520 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-05-28

Study results available
· View outcomes & findings →

Summary

The purpose of this project is to determine if a new combination of drugs, erlotinib (Tarceva™) and bevacizumab is safe and effective for treating women diagnosed with ovarian cancer whose cancer has progressed while on prior standard chemotherapy treatment with a taxane (paclitaxel or docetaxel) and a platinum (cisplatin or carboplatin).

Conditions

  • Ovarian Neoplasms

Interventions

DRUG

bevacizumab

10mg/kg every two weeks IV-bevacizumab

DRUG

erlotinib

150mg daily by mouth-erlotinib

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • University of Arizona

    lead OTHER

Principal Investigators

  • David S Alberts, MD · University of Arizona

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2010-01-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00130520 on ClinicalTrials.gov